Yuviwel (Navepegritide) FDA Approval for Achondroplasia

Significance of Yuviwel Approval

The FDA approval of Navepegritide (Yuviwel) is a landmark event for the achondroplasia community. As a first-in-class synthetic peptide, it specifically addresses the underlying genetic cause of impaired bone growth by counteracting overactive FGFR3 signaling. This once-weekly treatment offers renewed hope for children aged 2 and older with open epiphyses, potentially improving their growth and long-term health outcomes.

Event Details

• Drug Name: Navepegritide (Yuviwel)
• Developer: Ascendis Pharma
• Indication: Achondroplasia (patients ≥2 years with open epiphyses)
• Mechanism: Provides continuous systemic exposure to C-type natriuretic peptide (CNP)
• Dosage: Once-weekly treatment

FAQ

What is Yuviwel? Yuviwel is a first-in-class synthetic peptide approved for the treatment of achondroplasia.

How does Yuviwel work? It works by providing C-type natriuretic peptide (CNP), which counteracts the overactive FGFR3 signaling responsible for impaired bone growth.

Who can use Yuviwel? It is approved for patients aged 2 years and older with achondroplasia and open epiphyses.